Otto O Yang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8124558/publications.pdf

Version: 2024-02-01

165 papers	7,968 citations	61984 43 h-index	56724 83 g-index
175 all docs	175 docs citations	175 times ranked	12201 citing authors

#	Article	IF	Citations
1	Rapid Decay of Antiâ€“SARS-CoV-2 Antibodies in Persons with Mild Covid-19. New England Journal of Medicine, 2020, 383, 1085-1087.	27.0	986
2	Hydrodynamic stretching of single cells for large population mechanical phenotyping. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7630-7635.	7.1	669
3	Î²-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature, 1998, 391, 908-911.	27.8	297
4	Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication. Nature Nanotechnology, 2013, 8, 187-192.	31.5	289
5	Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1813-1818.	7.1	287
6	Gag-Specific CD8+ T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression. Journal of Immunology, 2007, 178, 2746-2754.	0.8	247
7	Good's syndrome remains a mystery after 55Âyears: A systematic review of the scientific evidence. Clinical Immunology, 2010, 135, 347-363.	3.2	209
8	Telomerase-Based Pharmacologic Enhancement of Antiviral Function of Human CD8+ T Lymphocytes. Journal of Immunology, 2008, 181, 7400-7406.	0.8	156
9	Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine, 2011, 9, 208.	4.4	143
10	The Î¸-Defensin, Retrocyclin, Inhibits HIV-1 Entry. AIDS Research and Human Retroviruses, 2003, 19, 875-881.	1.1	138
11	A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood, 2010, 115, 1534-1544.	1.4	132
12	Determinants of HIV-1 Mutational Escape From Cytotoxic T Lymphocytes. Journal of Experimental Medicine, 2003, 197, 1365-1375.	8.5	121
13	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 1365-1376.	10.7	119
14	HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. Molecular Therapy, 2015, 23, 1358-1367.	8.2	111
15	Nef-Mediated Resistance of Human Immunodeficiency Virus Type 1 to Antiviral Cytotoxic T Lymphocytes. Journal of Virology, 2002, 76, 1626-1631.	3.4	104
16	Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clinical Infectious Diseases, 2015, 61, 651-660.	5.8	103
17	CD8+ Cells in Human Immunodeficiency Virus Type I Pathogenesis: Cytolytic and Noncytolytic Inhibition of Viral Replication. Advances in Immunology, 1997, 66, 273-311.	2.2	100
18	Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. Journal of Infectious Diseases, 2015, 212, 1241-1249.	4.0	100

#	Article	IF	Citations
19	Intrinsic Human Immunodeficiency Virus Type 1 Resistance of Hematopoietic Stem Cells Despite Coreceptor Expression. Journal of Virology, 1999, 73, 728-737.	3.4	99
20	Optimization of methods to assess human mucosal T-cell responses to HIV infection. Journal of Immunological Methods, 2003, 279, 17-31.	1.4	96
21	Risks Associated With Lentiviral Vector Exposures and Prevention Strategies. Journal of Occupational and Environmental Medicine, 2016, 58, 1159-1166.	1.7	94
22	Beyond Help: Direct Effector Functions of Human Immunodeficiency Virus Type 1-Specific CD4 + T Cells. Journal of Virology, 2004, 78, 8844-8851.	3.4	89
23	Impacts of Avidity and Specificity on the Antiviral Efficiency of HIV-1-Specific CTL. Journal of Immunology, 2003, 171, 3718-3724.	0.8	86
24	Differential Impairment of Lytic and Cytokine Functions in Senescent Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes. Journal of Virology, 2003, 77, 3077-3083.	3.4	80
25	HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. Journal of Virology, 2016, 90, 6999-7006.	3.4	80
26	Human Immunodeficiency Virus Type 1 Clade B Superinfection: Evidence for Differential Immune Containment of Distinct Clade B Strains. Journal of Virology, 2005, 79, 860-868.	3.4	79
27	In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells. PLoS Pathogens, 2012, 8, e1002649.	4.7	74
28	A biochemical fluorometric method for assessing the oxidative properties of HDL. Journal of Lipid Research, 2011, 52, 2341-2351.	4.2	70
29	Clinical efficacy of gene-modified stem cells in adenosine deaminaseâ€“deficient immunodeficiency. Journal of Clinical Investigation, 2017, 127, 1689-1699.	8.2	70
30	Will we be able to â€˜spotâ€™ an effective HIV-1 vaccine?. Trends in Immunology, 2003, 24, 67-72.	6.8	69
31	Epitope Escape Mutation and Decay of Human Immunodeficiency Virus Type 1-Specific CTL Responses. Journal of Immunology, 2003, 171, 5372-5379.	0.8	68
32	Epitope-Dependent Avidity Thresholds for Cytotoxic T-Lymphocyte Clearance of Virus-Infected Cells. Journal of Virology, 2007, 81, 4973-4980.	3.4	67
33	CD1d on Myeloid Dendritic Cells Stimulates Cytokine Secretion from and Cytolytic Activity of VÎ±24JÎ±Q T Cells: A Feedback Mechanism for Immune Regulation. Journal of Immunology, 2000, 165, 3756-3762.	0.8	60
34	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. ACS Nano, 2021, 15, 11180-11191.	14.6	60
35	Decreased perforin and granzyme B expression in senescent HIV-1-specific cytotoxic T lymphocytes. Virology, 2005, 332, 16-19.	2.4	59
36	Parallel Human Immunodeficiency Virus Type 1-Specific CD8 + T-Lymphocyte Responses in Blood and Mucosa during Chronic Infection. Journal of Virology, 2005, 79, 4289-4297.	3.4	58

#	Article	IF	Citations
37	Nef interference with HIV-1â€“specific CTL antiviral activity is epitope specific. Blood, 2006, 108, 3414-3419.	1.4	58
38	Enhanced Inhibition of Human Immunodeficiency Virus Type 1 by Met-Stromal-Derived Factor 1Î² Correlates with Down-Modulation of CXCR4. Journal of Virology, 1999, 73, 4582-4589.	3.4	57
39	Immunomodulation of Antiretroviral Drug-Suppressed Chronic HIV-1 Infection in an Oral Probiotic Double-Blind Placebo-Controlled Trial. AIDS Research and Human Retroviruses, 2014, 30, 988-995.	1.1	56
40	Bronchoalveolar Immunologic Profile of Acute Human Lung Transplant Allograft Rejection. Transplantation, 2008, 85, 1056-1059.	1.0	52
41	Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice. PLoS ONE, 2009, 4, e8208.	2.5	51
42	Engineering the Human Thymic Microenvironment to Support Thymopoiesis In Vivo. Stem Cells, 2014, 32, 2386-2396.	3.2	50
43	Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. Diagnostic Microbiology and Infectious Disease, 2011, 71, 286-290.	1.8	46
44	HIV-1 Adapts to a Retrocyclin with Cationic Amino Acid Substitutions That Reduce Fusion Efficiency of gp41. Journal of Immunology, 2006, 176, 6900-6905.	0.8	45
45	Crossâ€Clade Detection of HIVâ€1â€“Specific Cytotoxic T Lymphocytes Does Not Reflect Crossâ€Clade Antiviral Activity. Journal of Infectious Diseases, 2008, 197, 390-397.	4.0	45
46	Antigen-Presenting Cell Candidates for HIV-1 Transmission in Human Distal Colonic Mucosa Defined by CD207 Dendritic Cells and CD209 Macrophages. AIDS Research and Human Retroviruses, 2014, 30, 241-249.	1.1	44
47	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. Journal of Virology, 2015, 89, 8643-8650.	3.4	42
48	Efficient Processing of the Immunodominant, HLA-A*0201-Restricted Human Immunodeficiency Virus Type 1 Cytotoxic T-Lymphocyte Epitope despite Multiple Variations in the Epitope Flanking Sequences. Journal of Virology, 1999, 73, 10191-10198.	3.4	42
49	Distinct aging profiles of CD8+ T cells in blood versus gastrointestinal mucosal compartments. PLoS ONE, 2017, 12, e0182498.	2.5	41
50	Early Antigen Presentation of Protective HIV-1 KF11Gag and KK10Gag Epitopes from Incoming Viral Particles Facilitates Rapid Recognition of Infected Cells by Specific CD8⁺T Cells. Journal of Virology, 2013, 87, 2628-2638.	3.4	40
51	Generation of T Lineage Cells from Human Embryonic Stem Cells in a Feeder Free System. Stem Cells, 2009, 27, 100-107.	3.2	39
52	How Many Human Immunodeficiency Virus Type 1-Infected Target Cells Can a Cytotoxic T-Lymphocyte Kill?. Journal of Virology, 2005, 79, 13579-13586.	3.4	38
53	Early HLA-B*57-Restricted CD8⁺T Lymphocyte Responses Predict HIV-1 Disease Progression. Journal of Virology, 2012, 86, 10505-10516.	3.4	38
54	Demographics and natural history of HIV-1-infected spontaneous controllers of viremia. Aids, 2017, 31, 1091-1098.	2.2	38

#	Article	IF	Citations
55	Genetic and Stochastic Influences on the Interaction of Human Immunodeficiency Virus Type 1 and Cytotoxic T Lymphocytes in Identical Twins. Journal of Virology, 2005, 79, 15368-15375.	3.4	37
56	Candidate Vaccine Sequences to Represent Intra- and Inter-Clade HIV-1 Variation. PLoS ONE, 2009, 4, e7388.	2.5	37
57	Introduction of Exogenous T-cell Receptors Into Human Hematopoietic Progenitors Results in Exclusion of Endogenous T-cell Receptor Expression. Molecular Therapy, 2013, 21, 1055-1063.	8.2	36
58	Functional Adaptation of Nef to the Immune Milieu of HIV-1 Infection In Vivo. Journal of Immunology, 2008, 180, 4075-4081.	0.8	35
59	Impacts of Epitope Expression Kinetics and Class I Downregulation on the Antiviral Activity of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes. Journal of Virology, 2004, 78, 561-567.	3.4	34
60	Immunologic Profile of Highly Exposed Yet HIV Type 1-Seronegative Men. AIDS Research and Human Retroviruses, 2002, 18, 1051-1065.	1.1	33
61	T Lymphocyte Density and Distribution in Human Colorectal Mucosa, and Inefficiency of Current Cell Isolation Protocols. PLoS ONE, 2015, 10, e0122723.	2.5	33
62	Protection against Bronchiolitis Obliterans Syndrome Is Associated with Allograft CCR7+CD45RAâ^' T Regulatory Cells. PLoS ONE, 2010, 5, e11354.	2.5	32
63	Monocyte Chemoattractant Proteinâ€“2 (CC Chemokine Ligand 8) Inhibits Replication of Human Immunodeficiency Virus Type 1 via CC Chemokine Receptor 5. Journal of Infectious Diseases, 2002, 185, 1174-1178.	4.0	28
64	Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes. Aids, 2010, 24, 2619-2628.	2.2	28
65	The systemic inflammatory landscape of COVID-19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2. Cell Reports Medicine, 2021, 2, 100453.	6.5	28
66	Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses. Journal of Virological Methods, 2003, 110, 137-142.	2.1	27
67	Degeneracy and Repertoire of the Human HIV-1 Gag p1777â€“85CTL Response. Journal of Immunology, 2006, 176, 6690-6701.	0.8	27
68	Short Conserved Sequences of HIV-1 Are Highly Immunogenic and Shift Immunodominance. Journal of Virology, 2015, 89, 1195-1204.	3.4	27
69	A novel small reporter gene and HIV-1 fitness assay. Journal of Virological Methods, 2006, 133, 41-47.	2.1	25
70	Availability of a Diversely Avid CD8+ T Cell Repertoire Specific for the Subdominant HLA-A2-Restricted HIV-1 Gag p2419â€“27 Epitope. Journal of Immunology, 2007, 178, 7756-7766.	0.8	25
71	HIV-1 Quasispecies Delineation by Tag Linkage Deep Sequencing. PLoS ONE, 2014, 9, e97505.	2.5	25
72	CTL ontogeny and viral escape: implications for HIV-1 vaccine design. Trends in Immunology, 2004, 25, 138-142.	6.8	24

#	Article	IF	Citations
73	Increasing CTL Targeting of Conserved Sequences During Early HIV-1 Infection Is Correlated to Decreasing Viremia. AIDS Research and Human Retroviruses, 2011, 27, 391-398.	1.1	24
74	A High Throughput Biochemical Fluorometric Method for Measuring Lipid Peroxidation in HDL. PLoS ONE, 2014, 9, e111716.	2.5	24
75	Persistent alterations in the T-cell repertoires of HIV-1-infected and at-risk uninfected men. Aids, 2004, 18, 161-170.	2.2	23
76	Delayed Reconstitution of CD4+ iNKT Cells after Effective HIV Type 1 Therapy. AIDS Research and Human Retroviruses, 2007, 23, 913-922.	1.1	23
77	Immune Selection In Vitro Reveals Human Immunodeficiency Virus Type 1 Nef Sequence Motifs Important for Its Immune Evasion Function In Vivo. Journal of Virology, 2012, 86, 7126-7135.	3.4	23
78	Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab. Clinical Infectious Diseases, 2021, 73, e4082-e4089.	5.8	23
79	Autologous CD4/CD8 co-culture assay: A physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons. Journal of Immunological Methods, 2007, 327, 75-81.	1.4	22
80	Broadly Increased Sensitivity to Cytotoxic T Lymphocytes Resulting from Nef Epitope Escape Mutations. Journal of Immunology, 2003, 171, 3999-4005.	0.8	21
81	Rapid T Cell Receptor Delineation Reveals Clonal Expansion Limitation of the Magnitude of the HIV-1â€“Specific CD8+ T Cell Response. Journal of Immunology, 2010, 185, 5935-5942.	0.8	21
82	Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes. Blood, 2012, 120, 100-111.	1.4	21
83	Robust CAR-T memory formation and function via hematopoietic stem cell delivery. PLoS Pathogens, 2021, 17, e1009404.	4.7	19
84	Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. Frontiers in Immunology, 2022, 13, 835830.	4.8	19
85	TCRÎ³Î´+and CD161+Thymocytes Express HIV-1 in the SCID-hu Mouse, Potentially Contributing to Immune Dysfunction in HIV Infection. Journal of Immunology, 2002, 169, 5338-5346.	0.8	18
86	Evasion of cytotoxic T lymphocytes is a functional constraint maintaining HIV-1 Nef expression. European Journal of Immunology, 2005, 35, 3221-3228.	2.9	18
87	Inhibition of Human Immunodeficiency Virus Type 1 Replication in Primary CD4+ T Lymphocytes, Monocytes, and Dendritic Cells by Cytotoxic T Lymphocytes. Journal of Virology, 2000, 74, 6695-6699.	3.4	17
88	Effects of Mutations on Replicative Fitness and Major Histocompatibility Complex Class I Binding Affinity Are Among the Determinants Underlying Cytotoxic-T-Lymphocyte Escape of HIV-1 Gag Epitopes. MBio, 2017, 8, .	4.1	17
89	Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection. PLoS ONE, 2021, 16, e0259703.	2.5	17
90	Hdl Redox Activity is Increased in HIV-Infected Men in Association with Macrophage Activation and Non-Calcified Coronary Atherosclerotic Plaque. Antiviral Therapy, 2014, 19, 805-811.	1.0	16

#	Article	IF	Citations
91	Ectopic expression of anti-HIV-1 shRNAs protects CD8+ T cells modified with CD4Î¶ CAR from HIV-1 infection and alleviates impairment of cell proliferation. Biochemical and Biophysical Research Communications, 2015, 463, 216-221.	2.1	16
92	Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes. Aids, 2008, 22, 325-331.	2.2	15
93	Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab. PLoS ONE, 2013, 8, e76829.	2.5	15
94	Supranormal thymic output up to 2 decades after HIV-1 infection. Aids, 2016, 30, 701-711.	2.2	15
95	Retracing our STEP towards a successful CTL-based HIV-1 vaccine. Vaccine, 2008, 26, 3138-3141.	3.8	14
96	Generation of robust CD8⁺ Tâ€cell responses against subdominant epitopes in conserved regions of HIVâ€1 by repertoire mining with mimotopes. European Journal of Immunology, 2010, 40, 1950-1962.	2.9	14
97	HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. Journal of Virology, 2017, 91, .	3.4	14
98	Solution Structures of Engineered Vault Particles. Structure, 2018, 26, 619-626.e3.	3.3	14
99	Differential Blood and Mucosal Immune Responses against an HIV-1 Vaccine Administered via Inguinal or Deltoid Injection. PLoS ONE, 2014, 9, e88621.	2.5	14
100	Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants. MBio, 2021, 12, e0265621.	4.1	14
101	Exposure to Wild Primates among HIV-infected Persons. Emerging Infectious Diseases, 2007, 13, 1579-1582.	4.3	13
102	Perturbations of Circulating Levels of RANKL-Osteoprotegerin Axis in Relation to Lipids and Progression of Atherosclerosis in HIV-Infected and -Uninfected Adults: ACTG NWCS 332/A5078 Study. AIDS Research and Human Retroviruses, 2013, 29, 938-948.	1.1	13
103	Untrained young men have dysfunctional HDL compared with strength-trained men irrespective of body weight status. Journal of Applied Physiology, 2013, 115, 1043-1049.	2.5	13
104	Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. Bioconjugate Chemistry, 2019, 30, 2216-2227.	3.6	13
105	Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector. Vaccine, 2009, 27, 3992-4000.	3.8	12
106	HIV-1 epitopes presented by MHC class I types associated with superior immune containment of viremia have highly constrained fitness landscapes. PLoS Pathogens, 2017, 13, e1006541.	4.7	12
107	HLA-Eâ€“restricted HIV-1â€“specific CD8+ T cell responses in natural infection. Journal of Clinical Investigation, 2021, 131, .	8.2	12
108	Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments. Vaccine, 2008, 26, 4617-4623.	3.8	11

#	Article	IF	Citations
109	Simultaneous assessment of CD4 and MHC-I downregulation by Nef primary isolates in the context of infection. Journal of Virological Methods, 2009, 161, 297-304.	2.1	11
110	Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s. Antiviral Therapy, 2017, 22, 113-126.	1.0	11
111	Highly Human Immunodeficiency Virus-Exposed Seronegative Men Have Lower Mucosal Innate Immune Reactivity. AIDS Research and Human Retroviruses, 2017, 33, 788-795.	1.1	11
112	Detection of HIV-1-specific CTL responses in Clade B infection with Clade C Peptides and not Clade B consensus peptides. Journal of Immunological Methods, 2005, 296, 1-10.	1.4	10
113	HIV-1 Gag Cytotoxic T Lymphocyte Epitopes Vary in Presentation Kinetics Relative to HLA Class I Downregulation. Journal of Virology, 2013, 87, 8726-8734.	3.4	10
114	HIV-1 Nef Sequence and Functional Compartmentalization in the Gut Is Not Due to Differential Cytotoxic T Lymphocyte Selective Pressure. PLoS ONE, 2013, 8, e75620.	2.5	10
115	Seminal Plasma HIV-1 RNA Concentration Is Strongly Associated with Altered Levels of Seminal Plasma Interferon-Î³, Interleukin-17, and Interleukin-5. AIDS Research and Human Retroviruses, 2014, 30, 1082-1088.	1.1	10
116	Highly Attenuated Infection With a Vpr-Deleted Molecular Clone of Human Immunodeficiency Virus-1. Journal of Infectious Diseases, 2018, 218, 1447-1452.	4.0	10
117	Chimeric Antigen Receptors Targeting Human Cytomegalovirus. Journal of Infectious Diseases, 2020, 222, 853-862.	4.0	10
118	Effects of HIV-1 infection on lymphocyte phenotypes in blood versus lymph nodes. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 507-18.	2.1	10
119	Chimeric immune receptor T cells bypass class I requirements and recognize multiple cell types relevant in HIV-1 infection. Virology, 2003, 306, 371-375.	2.4	9
120	Clonal breadth of the HIV-1-specific T-cell receptor repertoire in vivo as determined by subtractive analysis. Aids, 2005, 19, 887-896.	2.2	9
121	Proliferation and Foxp3 Expression in Virus-Specific Memory CD8+ T Lymphocytes. AIDS Research and Human Retroviruses, 2008, 24, 1087-1095.	1.1	9
122	Functional Analysis of HIV Type 1 Nef Gene Variants from Adolescent and Adult Survivors of Perinatal Infection. AIDS Research and Human Retroviruses, 2012, 28, 486-492.	1.1	9
123	Adenovirus vectors as HIV-1 vaccines. Aids, 2015, 29, 395-400.	2.2	9
124	Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Journal of Infectious Diseases, 2016, 214, 748-752.	4.0	9
125	Pediatric HIV-1â€“Specific Cytotoxic T-Lymphocyte Responses Suggesting Ongoing Viral Replication Despite Combination Antiretroviral Therapy. Pediatric Research, 2007, 61, 692-697.	2.3	8
126	Antiviral Activity of Human Immunodeficiency Virus Type 1 Gag-Specific Cytotoxic T Lymphocyte Targeting Is Not Necessarily Intrinsically Superior to Envelope Targeting. Journal of Virology, 2011, 85, 2474-2478.	3.4	8

#	Article	IF	Citations
127	Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. AIDS Reviews, 2014, 16, 123-33.	1.0	8
128	Antibacterial activity of peptides derived from envelope glycoproteins of HIV-1. FEBS Letters, 2003, 535, 195-199.	2.8	7
129	Primary Human Immunodeficiency Virus Type 1 (HIV-1) Infection during HIV-1 Gag Vaccination. Journal of Virology, 2008, 82, 2784-2791.	3.4	7
130	Predicting the Impact of Blocking Human Immunodeficiency Virus Type 1 Nef In Vivo. Journal of Virology, 2009, 83, 2349-2356.	3.4	7
131	In Vitro Inhibition of HIV-1 by Met-Sdf-1Î² Alone or in Combination with Antiretroviral Drugs. Antiviral Therapy, 2000, 5, 199-204.	1.0	7
132	Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine â€œresponseâ€. Vaccine, 2006, 24, 3426-3431.	3.8	6
133	Partial Escape of HIV-1 from Cytotoxic T Lymphocytes during Chronic Infection. Journal of Virology, 2012, 86, 7459-7463.	3.4	6
134	A Stochastic Multi-Scale Model of HIV-1 Transmission for Decision-Making: Application to a MSM Population. PLoS ONE, 2013, 8, e70578.	2.5	6
135	Clonal CD8+ T Cell Persistence and Variable Gene Usage Bias in a Human Transplanted Hand. PLoS ONE, 2015, 10, e0136235.	2.5	6
136	Human immune compartment comparisons: Optimization of proliferative assays for blood and gut T lymphocytes. Journal of Immunological Methods, 2017, 445, 77-87.	1.4	6
137	Assessing the Antiviral Activity of HIV-1-Specific Cytotoxic T Lymphocytes. Methods in Molecular Biology, 2009, 485, 407-415.	0.9	6
138	Culturing of HIV-1-specific cytotoxic T lymphocytes with interleukin-7 and interleukin-15. Virology, 2004, 325, 175-180.	2.4	5
139	Interferon-Î³ decreases replication of primary R5 HIV-1 isolates in thymocytes. Aids, 2006, 20, 939-942.	2.2	5
140	Paradoxical Effects of Two Theta-Defensins on HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2007, 23, 508-514.	1.1	5
141	Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study. HIV Clinical Trials, 2016, 17, 225-232.	2.0	5
142	HIV-1 Epitope Variability Is Associated with T Cell Receptor Repertoire Instability and Breadth. Journal of Virology, 2017, 91, .	3.4	5
143	Serological Responses to Toxoplasma gondii and Matrix Antigen 1 Predict the Risk of Subsequent Toxoplasmic Encephalitis in People Living With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 73, e2270-e2277.	5.8	5
144	Longitudinal Analysis of the T-cell Receptor Repertoire in Graft-infiltrating Lymphocytes Following Hand Transplantation. Transplantation, 2021, 105, 1502-1509.	1.0	5

#	Article	IF	Citations
145	Longitudinal COVID-19 Surveillance and Characterization in the Workplace with Public Health and Diagnostic Endpoints. MSphere, 2021, 6, e0054221.	2.9	5
146	Combination of allele-specific detection techniques to quantify minority resistance variants in hepatitis B infection: A novel approach. Journal of Virological Methods, 2013, 190, 34-40.	2.1	4
147	Ineffectual Targeting of HIV-1 Nef by Cytotoxic T Lymphocytes in Acute Infection Results in No Functional Impairment or Viremia Reduction. Journal of Virology, 2014, 88, 7881-7892.	3.4	4
148	Detection of Donor-Derived Microparticles in the Peripheral Blood of a Hand Transplant Recipient During Rejection. Transplantation Direct, 2017, 3, e131.	1.6	4
149	Disruption of an env tyrosine-dependent sorting signal does not affect susceptibility of HIV-1 to cytotoxic T lymphocytes. Aids, 2009, 23, 1449-1451.	2.2	3
150	Interleukin-2-unresponsive immune defects in good syndrome: Letter to the Editor. Clinical Immunology, 2010, 135, 496-498.	3.2	3
151	Human leukocyte antigen class I haplotypes of human immunodeficiency virusâ€“1â€“infected persons on Likoma Island, Malawi. Human Immunology, 2011, 72, 877-880.	2.4	3
152	Cross-Reactivity against Multiple HIV-1 Epitopes Is Characteristic of HIV-1-Specific Cytotoxic T Lymphocyte Clones. Journal of Virology, 2018, 92, .	3.4	3
153	Nef-induced differential gene expression in primary CD4+ T cells following infection with HIV-1 isolates. Virus Genes, 2019, 55, 541-544.	1.6	3
154	War in the Body. , 2013, , .		2
155	Short Communication: HIV-1 Gag Genetic Variation in a Single Acutely Infected Participant Defined by High-Resolution Deep Sequencing. AIDS Research and Human Retroviruses, 2014, 30, 806-811.	1.1	2
156	Reimann's â€œHabitual Hyperthermiaâ€•Responding to Hormone Therapy. Open Forum Infectious Diseases, 2016, 3, ofw127.	0.9	2
157	CD8+Cytotoxic T Lymphocyte Responses and Viral Epitope Escape in Acute HIV-1 Infection. Viral Immunology, 2018, 31, 525-536.	1.3	2
158	A Novel HIV-1 Nef Mutation in a Primary Pediatric Isolate Impairs MHC-Class I Downregulation and Cytopathicity. AIDS Research and Human Retroviruses, 2020, 36, 122-130.	1.1	0
159	HIV-1-Specific CTL Recognizing a Scarce Epitope Are Not Suppressed by HIV-1 Protease Inhibitors. American Journal of Immunology, 2007, 3, 1-3.	0.1	0
160	Understanding Escape. , 2013, , 81-96.		0
161	Retroviral Sex and Escape. , 2013, , 123-134.		0
162	Engineering The Human Thymic Microenvironment To Support Thymopoiesis. Blood, 2013, 122, 3494-3494.	1.4	0

#	Article	IF	Citations
163	HSC Clonal Dynamics after T-Cell Depletion in a Nonhuman Primate Model of Lentiviral Gene Therapy. Blood, 2016, 128, 3702-3702.	1.4	0
164	COVID-19 vaccine dosage in children, adolescents, and young adults â€“ is less more?. Open Forum Infectious Diseases, 0, , .	0.9	0
165	Reply to Viel. Clinical Infectious Diseases, 0, , .	5.8	0